Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (vol 23, pg 857, 2016)

被引：0
|
作者：
Georgiadis, A.
Duran, Y.
Ribeiro, J.
Abelleira-Hervas, L.
Robbie, S. J.
Sunkel-Laing, B.
Fourali, S.
Gonzalez-Cordero, A.
Cristante, E.
Michaelides, M.
Bainbridge, J. W. B.
Smith, A. J.
Ali, R. R.
机构：
[1] UCL Institute of Ophthalmology,Department of Genetics
[2] NIHR Biomedical Research Centre at Moorfields Eye Hospital,undefined
来源：
GENE THERAPY | 2024年 / 31卷 / 9-10期
关键词：
D O I：
10.1038/s41434-024-00463-z
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：524 / 524
页数：1
相关论文
共 38 条
  • [1] Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (vol 23, pg 857, 2016)
    Georgiadis, A.
    Duran, Y.
    Ribeiro, J.
    Abelleira-Hervas, L.
    Robbie, S. J.
    Sunkel-Laing, B.
    Fourali, S.
    Gonzalez-Cordero, A.
    Cristante, E.
    Michaelides, M.
    Bainbridge, J. W. B.
    Smith, A. J.
    Ali, R. R.
    GENE THERAPY, 2018, 25 (06) : 450 - 450
  • [2] Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
    Georgiadis, A.
    Duran, Y.
    Ribeiro, J.
    Abelleira-Hervas, L.
    Robbie, S. J.
    Sunkel-Laing, B.
    Fourali, S.
    Gonzalez-Cordero, A.
    Cristante, E.
    Michaelides, M.
    Bainbridge, J. W. B.
    Smith, A. J.
    Ali, R. R.
    GENE THERAPY, 2016, 23 (12) : 857 - 862
  • [3] Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
    A Georgiadis
    Y Duran
    J Ribeiro
    L Abelleira-Hervas
    S J Robbie
    B Sünkel-Laing
    S Fourali
    A Gonzalez-Cordero
    E Cristante
    M Michaelides
    J W B Bainbridge
    A J Smith
    R R Ali
    Gene Therapy, 2016, 23 : 857 - 862
  • [4] Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
    A. Georgiadis
    Y. Duran
    J. Ribeiro
    L. Abelleira-Hervas
    S. J. Robbie
    B. Sünkel-Laing
    S. Fourali
    A. Gonzalez-Cordero
    E. Cristante
    M. Michaelides
    J. W. B. Bainbridge
    A. J. Smith
    R. R. Ali
    Gene Therapy, 2018, 25 : 450 - 450
  • [5] Treatment of Patients with Leber Congenital Amaurosis Type 2 with an AAV Vector Expressing RPE65
    Stout, Tim
    Weleber, Richard
    McBride, Maureen
    Wilson, David
    Peters, Dawn
    Humphries, Margaret
    Flotte, Terence
    Jensen, Lauren
    Lauer, Andreas
    Chulay, Jeffrey
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [6] Long-term effect of gene therapy on Leber congenital amaurosis caused by defects in RPE65
    Bainbridge, James W. B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [7] Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
    Cideciyan, Artur V.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (05) : 398 - 427
  • [8] Improved vision following RPE65 gene therapy in adults with Leber congenital amaurosis
    Ali, Robin
    Bainbridge, James
    Rubin, Gary
    Robbie, Scott
    Barker, Susan
    Holder, Graham
    Stockman, Andrew
    Moore, Anthony
    Smith, Alexander
    Moore, Anthony
    HUMAN GENE THERAPY, 2008, 19 (10) : 1060 - 1060
  • [9] Pre-clinical toxicology of AAV2/5-OPTIRPE65, an optimised RPE65 gene therapy vector
    Georgiadis, A.
    Duran, Y.
    Ribeiro, J.
    Abelleira, L.
    Naylor, S.
    Smith, A. J.
    Bainbridge, J. W. B.
    Ali, R. R.
    HUMAN GENE THERAPY, 2017, 28 (12) : A77 - A77
  • [10] rAAV mediated RPE65 gene therapy of mouse and dog models of Leber's Congenital Amaurosis
    Rakoczy, EP
    Lai, CM
    Brankov, M
    Redmond, MT
    Zhou, X
    Narfstrom, K
    JOURNAL OF GENE MEDICINE, 2003, 5 (05): : S5 - S5
1234